*OMG* Sanofi-Aventis at %4.37 Yield?
March 04, 2010
– Comments (5) |
RELATED TICKERS: SNY
For whatever reason.... and despite Berkshire Hathaway increasing their stake in Sanofi-Aventis, positive news on their pipeline drug for prostate cancer Cabazitaxel, a below 14 P/E, and $2.46 Cash per Share, this stock continues to underperform the S&P 500.... Taking a wallop today with a loss of 1.09% on their share price.
Taking a look at the chart and how can your eyes not fall out of their sockets and land on the BUY BUY BUY Button on your keyboard?? what??? You don't have a *BUY* button on your keyboard?
Oh that's right... you are the investor still screaming, "BEAR MARKET RALLY!!!!! This Stock Market Rally is BUNK!!!!"
But for those of us who want to make money in the BIOTECH sector... Sanofi-Aventis looks awfully apetising right now.
Standard and Poors currently as a $40 price target.
Why shouldn't this stock be bought at this price today?
DISCLOSURE: I own ZERO shares of SNY but obviously I am thinking about owning some.